| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Nadiya Ye Barabash, Tetiana M Tykhonov. Experience with Dopamine Agonists in the Treatment of Prolactinomas. Acta medica Lituanica. vol 29. issue 2. 2023-09-21. PMID:37733390. |
experience with dopamine agonists in the treatment of prolactinomas. |
2023-09-21 |
2023-10-07 |
Not clear |
| Ilan Shimo. Prolactinomas Resistant to Dopamine Agonists: Pathophysiology and Treatment. Archives of medical research. 2023-09-09. PMID:37689507. |
prolactinomas resistant to dopamine agonists: pathophysiology and treatment. |
2023-09-09 |
2023-10-07 |
Not clear |
| Ilan Shimo. Prolactinomas Resistant to Dopamine Agonists: Pathophysiology and Treatment. Archives of medical research. 2023-09-09. PMID:37689507. |
the expression of dopamine (d2) receptors and dopamine affinity is decreased in aggressive and resistant prolactinomas. |
2023-09-09 |
2023-10-07 |
Not clear |
| Stephan Petersenn, Maria Fleseriu, Felipe F Casanueva, Andrea Giustina, Nienke Biermasz, Beverly M K Biller, Marcello Bronstein, Philippe Chanson, Hidenori Fukuoka, Monica Gadelha, Yona Greenman, Mark Gurnell, Ken K Y Ho, Jürgen Honegger, Adriana G Ioachimescu, Ursula B Kaiser, Niki Karavitaki, Laurence Katznelson, Maya Lodish, Dominique Maiter, Hani J Marcus, Ann McCormack, Mark Molitch, Christopher A Muir, Sebastian Neggers, Alberto M Pereira, Rosario Pivonello, Kalmon Post, Gerald Raverot, Roberto Salvatori, Susan L Samson, Ilan Shimon, Joanna Spencer-Segal, Greisa Vila, John Wass, Shlomo Melme. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nature reviews. Endocrinology. 2023-09-05. PMID:37670148. |
in-depth discussions present the latest evidence on treatment of prolactinoma, including efficacy, adverse effects and options for withdrawal of dopamine agonist therapy, as well as indications for surgery, preoperative medical therapy and radiation therapy. |
2023-09-05 |
2023-10-07 |
Not clear |
| Ozlem Soyluk, Zuleyha Bingol, Sema Ciftci, Neslihan Kurtulmus, Seher Tanrikulu, Sema Yarma. Evaluation of pulmonary side effects in prolactinoma patients treated with cabergoline. Endokrynologia Polska. 2023-08-14. PMID:37577991. |
cabergoline (cab) is the most used dopamine agonist in the treatment of prolactinomas. |
2023-08-14 |
2023-08-16 |
Not clear |
| Eui Hyun Kim, Junhyung Kim, Cheol Ryong Ku, Eun Jig Lee, Sun Ho Ki. Surgical Treatment of Prolactinomas: Potential Role as a First-Line Treatment Modality. Yonsei medical journal. vol 64. issue 8. 2023-07-25. PMID:37488700. |
treatment with dopamine agonists (das) has been the first-line standard treatment for prolactinoma, and surgery has been reserved for drug intolerance and resistance for several decades. |
2023-07-25 |
2023-08-14 |
Not clear |
| Tomoko Nagamine, Izumi Fukud. [Medical Therapies in Functioning Pituitary Neuroendocrine Tumors(PitNETs)]. No shinkei geka. Neurological surgery. vol 51. issue 4. 2023-07-25. PMID:37491068. |
dopamine agonists(da)are the first-line treatment for prolactinomas. |
2023-07-25 |
2023-08-14 |
Not clear |
| Chayma Belhadj Slimane, Ibtissem Oueslati, Meriem Yazidi, Elyes Kamoun, Melika Chihaou. De Novo Psychiatric Disorders in a Woman With Giant Prolactinoma Treated With Cabergoline. Clinical medicine insights. Case reports. vol 16. 2023-07-17. PMID:37457316. |
dopamine agonists are the first-line treatment of prolactinomas. |
2023-07-17 |
2023-08-14 |
Not clear |
| Annabelle G Hayes, Masoumeh G Shirazi, Anand Thiyagarajah, David J Torpy, Sunita M C De Sous. Cabergoline-associated valvulopathy of the tricuspid valve in the treatment of prolactinoma. Endocrine oncology (Bristol, England). vol 3. issue 1. 2023-07-12. PMID:37434646. |
while it is a well-described complication of dopamine agonist therapy in parkinson's disease, only three convincing cases of cav have previously been described in the treatment of prolactinoma, with none involving the tricuspid valve. |
2023-07-12 |
2023-08-14 |
Not clear |
| Annabelle G Hayes, Masoumeh G Shirazi, Anand Thiyagarajah, David J Torpy, Sunita M C De Sous. Cabergoline-associated valvulopathy of the tricuspid valve in the treatment of prolactinoma. Endocrine oncology (Bristol, England). vol 3. issue 1. 2023-07-12. PMID:37434646. |
the risk of cav, although small, prompts a mindful prescription of dopamine agonist therapy for prolactinomas and consideration of measures to minimise cabergoline exposure. |
2023-07-12 |
2023-08-14 |
Not clear |
| Sunita M C De Sous. Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management? Endocrine oncology (Bristol, England). vol 2. issue 1. 2023-07-12. PMID:37435462. |
dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management? |
2023-07-12 |
2023-08-14 |
Not clear |
| Sunita M C De Sous. Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management? Endocrine oncology (Bristol, England). vol 2. issue 1. 2023-07-12. PMID:37435462. |
the current treatment paradigm for prolactinomas involves dopamine agonist (da) therapy as the first-line treatment, with surgical resection reserved for cases where there is da failure due to resistance or intolerance. |
2023-07-12 |
2023-08-14 |
Not clear |
| Malte Ottenhausen, Jens Conrad, Lea-Marie Wolters, Florian Ringe. Surgery as first-line treatment for prolactinoma? Discussion of the literature and results of a consecutive series of surgically treated patients. Neurosurgical review. vol 46. issue 1. 2023-05-30. PMID:37249700. |
initial treatment for prolactinoma is usually conservative with dopamine agonists. |
2023-05-30 |
2023-08-14 |
Not clear |
| Charles Springer, Robert Rodgers, Gina Vivino, Saritha Attanagoda, Charles Dylan Mik. A Case Report of Delusions in a Patient Receiving Cabergoline Therapy for Prolactinoma: Pathophysiology and Proposed Treatment With Aripiprazole. Clinical neuropharmacology. vol 46. issue 3. 2023-05-16. PMID:37191567. |
cabergoline is a dopamine 2 receptor agonist used as first-line treatment of pituitary prolactinomas. |
2023-05-16 |
2023-08-14 |
Not clear |
| Michelle D Lundholm, Divya Yogi-Morren, Kevin M Pantalone, Pablo F Recinos, Varun R Kshettry, Pratibha P R Ra. Surgical Management of Giant Prolactinomas: A Descriptive Study. International journal of endocrinology. vol 2023. 2023-05-05. PMID:37143698. |
giant prolactinoma (gp) is a rare pituitary lactotropic cell tumor larger than 4 cm in its widest dimension, and is less likely than a smaller prolactinoma to achieve prolactin normalization on dopamine agonist (da) monotherapy. |
2023-05-05 |
2023-08-14 |
Not clear |
| Dilan Demir, Ahmet Numan Demir, Cem Sulu, Guldana Zulfaliyeva, Semih Can Cetintas, Hande Mefkure Ozkaya, Pinar Kadioglu, Nurperi Gazioglu, Necmettin Tanriove. The Combination of Dopamine Agonist Treatment and Surgery May Be The Best Option in Challenging Prolactinoma Cases: A Single-Centre Experience. World neurosurgery. 2023-04-29. PMID:37120141. |
the combination of dopamine agonist treatment and surgery may be the best option in challenging prolactinoma cases: a single-centre experience. |
2023-04-29 |
2023-08-14 |
Not clear |
| Matheo Augusto Morandi Stumpf, Felipe Moura Maia Pinheiro, Gilberto Ochman Silva, Valter Angelo Sperling Cescato, Nina Rosa Castro Musolino, Malebranche Berardo Carneiro Cunha-Neto, Andrea Gleze. How to manage intolerance to dopamine agonist in patients with prolactinoma. Pituitary. 2023-04-07. PMID:37027090. |
how to manage intolerance to dopamine agonist in patients with prolactinoma. |
2023-04-07 |
2023-08-14 |
Not clear |
| Matheo Augusto Morandi Stumpf, Felipe Moura Maia Pinheiro, Gilberto Ochman Silva, Valter Angelo Sperling Cescato, Nina Rosa Castro Musolino, Malebranche Berardo Carneiro Cunha-Neto, Andrea Gleze. How to manage intolerance to dopamine agonist in patients with prolactinoma. Pituitary. 2023-04-07. PMID:37027090. |
dopamine agonists (da) are the gold-standard for prolactinoma and hyperprolactinemia treatment. |
2023-04-07 |
2023-08-14 |
Not clear |
| Renata S Auriemma, Rosa Pirchio, Claudia Pivonello, Francesco Garifalos, Annamaria Colao, Rosario Pivonell. Approach to the Patient with Prolactinoma. The Journal of clinical endocrinology and metabolism. 2023-03-28. PMID:36974474. |
the treatment of choice for prolactinomas is represented by dopamine agonists, mainly cabergoline, able to induce disease control, restore fertility in both sexes, and definitively cure one-third of patients, thus permitting treatment discontinuation. |
2023-03-28 |
2023-08-14 |
Not clear |
| Dan Alexandru Niculescu, Monica Livia Gheorghiu, Catalina Poian. Radiotherapy in aggressive or dopamine agonists resistant prolactinomas; is it still worthwhile? European journal of endocrinology. 2023-03-28. PMID:36975104. |
radiotherapy in aggressive or dopamine agonists resistant prolactinomas; is it still worthwhile? |
2023-03-28 |
2023-08-14 |
Not clear |